Incyte Corp (NASDAQ:INCY)

CAPS Rating: 2 out of 5

The Company is a drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs.

Recs

0
Player Avatar TMFTycoon (31.65) Submitted: 3/20/2014 4:06:59 PM : Underperform Start Price: $63.48 INCY Score: +31.11

I think Incyte needs a secondary source of revenue besides its main drug, Jakafi, and in the meantime, shares have run up based on Jakafi's success.

Featured Broker Partners


Advertisement